A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Nemolizumab in Patients with Acquired Reactive Perforating Collagenosis

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2023
INTERVENTION: subcutaneous administration CONDITION: Acquired Reactive Perforating Collagenosis PRIMARY OUTCOME: Peak pruritus‐Numeric rate scale (PP‐NRS) INCLUSION CRITERIA: Patients aged 18 years or older who have been diagnosed with acquired reactive perforating collagen fibrosis according to the diagnostic criteria of the Clinical Practice Guide for Perforated Dermatoses (2020)
Epistemonikos ID: 54ece2e38293c817bf5bad381a1d64282e1af626
First added on: Aug 28, 2024